Press release
Health Care
Essen, Germany, October 2, 2024

Evonik establishes Global Competence Network for Cell Culture Solutions

  • First point of contact for partners seeking to manufacture cell culture-based therapies more efficiently
  • Draws on multidisciplinary team of experts
  • Drives the development of system solutions to address upstream challenges in cell culture

 

Evonik has established a new global network to develop system solutions that address upstream challenges in cell culture. The Global Competence Network for Cell Culture Solutions brings together a multidisciplinary team of business, application technology, and research and development experts in chemistry, cell biology, bioprocessing and media optimization across Asia, Europe and the Americas. The goal of the network is to empower customers to manufacture cell culture-based therapies more efficiently.

Optimizing cell culture media is a key strategy to ensure high yields and product quality for biopharmaceuticals. The new network will increase Evonik’s offering of system solutions for cell culture media. It also forms part of the company’s recently introduced “Advance Precision Biosolutions” innovation growth area within the life sciences division, Nutrition & Care. The growth area includes focusing on the development of biosurfactants, as well as cosmetic and pharmaceutical solutions that improve people's health and quality of life, save resources and protect ecosystems.

“With our new competence network, we go beyond by cross-connecting skills, driving innovation and sustainably propelling healthcare into the future,” said Hans Henning Wenk, Vice President R&D for the Health Care business at Evonik.

Evonik’s Global Competence Network for Cell Culture Solutions works with partners to address upstream challenges in cell culture such as process intensification and scalability. The network draws on a strong ingredient portfolio that includes the cQrex® peptides, plant-based cholesterol (PhytoChol®) and specialty carbohydrates, as well as R&D, formulation and process expertise. The network will be the primary resource for customers in need of system solutions that enhance their media and processes.

The network has multiple locations worldwide, with teams in Germany focusing primarily on CHO cell culture and analytics, complemented by cell and gene therapy application development in Singapore. A recent addition is an Innovation Satellite in Cambridge (MA) in the U.S., where Evonik's strategic innovation unit and business incubator, Creavis, will focus on R&D for nucleic acid-based medicines and cell culture solutions.

System solutions are tailored offerings that integrate products, technologies and services, and often have proven sustainability benefits. By focusing on system solutions, Evonik is positioning itself as a partner that supports customers from ideation to the finished product, enabling them to bring differentiated products to market more rapidly.

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.3 billion and an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. Around 32,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.61 billion in 2023 with more than 5,600 employees.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

More about Evonik's product and service portfolio for cell culture